{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:45:38Z","timestamp":1695746738594},"reference-count":18,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T00:00:00Z","timestamp":1412035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.<\/jats:p>","DOI":"10.4081\/hr.2014.5516","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T09:12:28Z","timestamp":1415351548000},"page":"5516","source":"Crossref","is-referenced-by-count":5,"title":["Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient"],"prefix":"10.3390","volume":"6","author":[{"given":"Harry Ross","family":"Powers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Bachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Dainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"Clin J Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1080\/1042819021000006529","article-title":"The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature","volume":"43","author":"Leopold","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ajh.23464","article-title":"Azacitidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy","volume":"88","author":"Ivanoff","year":"2013","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jgo.2013.08.004","article-title":"The role of hypomethylating agents in the treatment of elderly patients with AML","volume":"5","author":"Al-Ali","year":"2014","journal-title":"Geriatr J Oncol"},{"key":"ref8","first-page":"1803","article-title":"Spotlight on epigenetics in hematological malignancies","volume":"27","author":"Estey","year":"2013","journal-title":"Epigenentics in clinical practice: the example of azacytidine and decitabine. Leukemia"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-Azacytidine: a new anticancer drug with effectiveness in acute myelogenous leukemia","volume":"85","author":"Von Hoff","year":"1976","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute leukemia","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1054.1054","article-title":"Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program","volume":"114","author":"Itzykson","year":"2009","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.leukres.2008.01.004","article-title":"Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature","volume":"32","author":"Marbello","year":"2008","journal-title":"Leuk Res"},{"key":"ref13","first-page":"21","article-title":"A phase II trial of epigenetic modulators vorinostat with azacitidine in patients with the myelodysplastic syndrome: initial results of study 6898 of the New York cancer consortium","author":"Silverman","year":"2013","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.22197","article-title":"Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics","volume":"87","author":"Ghanem","year":"2012","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/ehm.12.45","article-title":"Molecular prognostic factors in cytogenetically normal acute myeloid leukemia","volume":"5","author":"Walker","year":"2012","journal-title":"Exp Rev Hematol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0165-4608(92)90208-P","article-title":"Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome","volume":"59","author":"Bellomo","year":"1992","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/5516\/4471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/6\/3\/5516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:56:08Z","timestamp":1645599368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/6\/3\/5516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,30]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["hr.2014.5516"],"URL":"https:\/\/doi.org\/10.4081\/hr.2014.5516","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,30]]}}}